Table 2.

Allosteric modulation involves the canonical agonist interface

Subtype	ACh Activation		ACh + Mor Modulation			Mor Activation
	EC₅₀ (µM)	n_H	EC₅₀ (µM)	n_H	_Eax	EC₅₀ (µM)	n_H	E_max
α3β2^a	66 ± 9	0.75 ± 0.07 [5–11]	10 ± 2	1.37 ± 0.80	2.64 ± 0.29 [5]	20 ± 2^b	3.1 ± 1.6	0.20 ± 0.04
α3S125Yβ2	7.6 ± 2.1	0.84 ± 0.19 [3–6]	8.8 ± 4.9nM	0.31 ± 0.05	1.41 ± 0.11 [3–6]	2.3 ± 0.7	1.58 ± 0.42 [3–4]	1.69 ± 0.27
α3S125Y· β2W149A	4.5 ± 1.4	0.61 ± 0.10 [6]	4.9 ± 2.0	0.72 ± 0.16 [5]	1.33 ± 0.10	25 ± 9	1.01 ± 0.29 [5–6]	0.21 ± 0.02
α3β2W149A ^a	40 ± 6	0.99 ± 0.12 [5]	44 ± 6	1.38 ± 0.19	0.86 ± 0.03 [5]	N.F.	N.F.	0.015 ± 0.004 [3]
α3S125C· β2Q39C	1.1 ± 0.2	0.66 ± 0.09 [3–7]	0.75 ± 0.40	0.62 ± 0.18 [4]	2.57 ± 0.17	0.53 ± 0.21	0.92 ± 0.30 [4–8]	1.00 ± 0.14
α3S125Cβ2	3.5 ± 1.3	0.64 ± 0.13 [5–7]	0.71 ± 0.20	0.85 ± 0.17	1.48 ± 0.07 [5]	92 ± 33	0.54 ± 0.11 [4]	0.028 ± 0.006
α3β2Q39C	130 ± 30	0.78 ± 0.12 [4]	2.0 ± 0.4	0.91 ± 0.15	2.54 ± 0.09 [6]	N.D.

Fits to the Hill equation for experiments with ACh alone, ACh + 10 µM Mor or Mor alone. In all experiments for the (α3S125Cβ2Q39C double mutant, recordings were made on naive oocytes, having had no previous oxidation or reduction treatment [n] indicates the number of replicate oocytes for each measurement. N.F. indicates no fit was possible for data collected in experiment; N.D. indicates no data were collected for experiment.

Data of ACh and ACh + Mor titrations for wild type α3β2, and all data α3β2W149A from 32.

Data of Mor titration for wild type α3β2 from 38.